13 Diabetics Implanted with VeriMed RFID Microchip at Boston Diabetes EXPO
March 19 2007 - 9:30AM
PR Newswire (US)
VeriChip Corporation continues to focus on diabetic patients to
provide important identification and medical record information
DELRAY BEACH, Fla., March 19 /PRNewswire-FirstCall/ -- VeriChip
Corporation (NASDAQ:CHIPNASDAQ:-NASDAQ:News), a provider of RFID
systems for healthcare and patient-related needs, announced today
it added 13 diabetic patients to its VeriMed Patient Identification
System network at a Boston Diabetes EXPO sponsored by the American
Diabetes Association (ADA). At the Boston Diabetes EXPO, physicians
implanted VeriMed RFID microchips in conference attendees who
signed up for the voluntary procedure. The VeriMed Patient
Identification System, which utilizes an implantable RFID microchip
in combination with a handheld RFID scanner and a secure patient
database, provides immediate access to important identification and
health information for patients who arrive at an emergency
department unable to communicate. Scott R. Silverman, Chairman and
CEO of VeriChip, commented, "We continue to expand our presence at
ADA events and focus on individuals with diabetes as we believe
they, and other high-risk populations, may benefit greatly from the
VeriMed Patient Identification System. Through the Atlanta and
Boston Diabetes EXPOs, we have now enrolled 31 more patients in our
system. Furthermore, these sign-ups by diabetic individuals
underscore the importance of our planned future development efforts
to commercialize a glucose-sensing implantable microchip, with our
sister company Digital Angel, which was awarded a patent on this
breakthrough product." The Diabetes EXPO is a patient-driven
tradeshow, including professional speakers and a variety of ADA
program/event information, where exhibitors from pharmaceutical and
medical device companies display beneficial products for diabetics.
The Diabetes EXPO began in 1995 in Phoenix, Arizona, and has grown
to 18, metro, major and mid-size cities around the U.S. The next
event will be held in Chicago on April 28, 2007. About VeriChip
Corporation VeriChip Corporation, headquartered in Delray Beach,
Florida, develops, markets and sells radio frequency
identification, or RFID, systems used to identify, locate and
protect people and assets. VeriChip's goal is to become the leading
provider of RFID systems for people in the healthcare industry.
VeriChip sells passive RFID systems for identification purposes and
active RFID systems for local-area location and identification
purposes. VeriChip recently began to market its VeriMed(TM) Patient
Identification System for rapidly and accurately identifying people
who arrive in an emergency room and are unable to communicate. This
system uses the first human-implantable passive RFID microchip, the
implantable VeriChip(TM), cleared for medical use in October 2004
by the United States Food and Drug Administration. VeriChip
Corporation is majority-owned by Applied Digital Inc. (NASDAQ:
ADSXNASDAQ:-NASDAQ:News), which also owns a majority position in
Digital Angel Corporation (AMEX:DOCAMEX:-AMEX:News). For more
information on VeriChip, please call 1-800-970- 2447, or email .
Additional information can be found online at
http://www.verichipcorp.com/. Statements about the Company's future
expectations, including future revenues and earnings, and all other
statements in this press release other than historical facts are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Litigation
Reform Act of 1995. Such forward-looking statements involve risks
and uncertainties and are subject to change at any time, and the
Company's actual results could differ materially from expected
results. The Company undertakes no obligation to update
forward-looking statements to reflect subsequently occurring events
or circumstances. VeriChip Corporation (NASDAQ:CHIP), a provider of
RFID systems for healthcare and patient-related needs, announced
today it added 18 diabetic patients to its VeriMed Patient
Identification System at an Atlanta Diabetes EXPO sponsored by the
American Diabetes Association (ADA). At the EXPO, physicians
implanted VeriMed RFID microchips in conference attendees who
signed up for the voluntary procedure. The VeriMed Patient
Identification System, which utilizes an implantable RFID microchip
in combination with a handheld RFID scanner and a secure patient
database, provides immediate access to important health information
for patients who arrive at an emergency department unable to
communicate. Scott R. Silverman, Chairman and CEO of VeriChip,
commented "We believe the VeriMed Patient Identification System is
an essential health care solution for at-risk patients, including
diabetics, who tend to present with various co-morbidities and
medications, and are more frequently admitted to emergency
departments. The ADA Diabetes EXPO provides us direct access so we
can continue to educate an important target audience." The Expo is
a patient-driven tradeshow, including professional speakers and a
variety of ADA program/event information, where exhibitors from
pharmaceutical and medical device companies display beneficial
products for diabetics. The Diabetes EXPO began in 1995 in Phoenix,
Arizona, and has grown to 18, metro, major and mid-size cities
around the U.S. The next event will be held in Boston on March 17.
About VeriChip Corporation VeriChip Corporation, headquartered in
Delray Beach, Florida, develops, markets and sells radio frequency
identification, or RFID, systems used to identify, locate and
protect people and assets. VeriChip's goal is to become the leading
provider of RFID systems for people in the healthcare industry.
VeriChip sells passive RFID systems for identification purposes and
active RFID systems for local-area location and identification
purposes. VeriChip recently began to market its VeriMed(TM) Patient
Identification System for rapidly and accurately identifying people
who arrive in an emergency room and are unable to communicate. This
system uses the first human-implantable passive RFID microchip, the
implantable VeriChip(TM), cleared for medical use in October 2004
by the United States Food and Drug Administration. VeriChip
Corporation is majority-owned by Applied Digital Inc. (NASDAQ:
ADSX), which also owns a majority position in Digital Angel
Corporation (AMEX: DOC). For more information on VeriChip, please
call 1-800-970-2447, or email . Additional information can be found
online at http://www.verichipcorp.com/. Statements about the
Company's future expectations, including future revenues and
earnings, and all other statements in this press release other than
historical facts are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934, and as that term is defined
in the Private Litigation Reform Act of 1995. Such forward-looking
statements involve risks and uncertainties and are subject to
change at any time, and the Company's actual results could differ
materially from expected results. The Company undertakes no
obligation to update forward-looking statements to reflect
subsequently occurring events or circumstances. Contact: VeriChip
Corporation Allison Tomek 561-805-8000 The Ruth Group Nick Laudico
(investors) (646) 536-7030 Jason Rando (media) (646) 536-7025
DATASOURCE: VeriChip Corporation CONTACT: VeriChip Corporation,
Allison Tomek, +1-561-805-8000, ; The Ruth Group, Nick Laudico
(investors), +1-646-536-7030, , or Jason Rando (media),
+1-646-536-7025, Web site: http://www.verichipcorp.com/
Copyright